There are many drugs that have been around for years and others with strong data awaiting FDA approval that are beneficial in treating conditions like atopic dermatitis and alopecia areata, said James Q. Del Rosso, DO.
Posters presented at Fall Clinical Dermatology 2023 found that dupilumab had effective and safe results when received in a 5-year period for atopic dermatitis.
New data on dupilumab demonstrate the drug’s potential usefulness in treating type 2 inflammation, a role central to respiratory diseases, including chronic obstructive pulmonary disease (COPD).